BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 12176671)

  • 1. Fenofibrate improves insulin sensitivity in connection with intramuscular lipid content, muscle fatty acid-binding protein, and beta-oxidation in skeletal muscle.
    Furuhashi M; Ura N; Murakami H; Hyakukoku M; Yamaguchi K; Higashiura K; Shimamoto K
    J Endocrinol; 2002 Aug; 174(2):321-9. PubMed ID: 12176671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fenofibrate lowers abdominal and skeletal adiposity and improves insulin sensitivity in OLETF rats.
    Lee HJ; Choi SS; Park MK; An YJ; Seo SY; Kim MC; Hong SH; Hwang TH; Kang DY; Garber AJ; Kim DK
    Biochem Biophys Res Commun; 2002 Aug; 296(2):293-9. PubMed ID: 12163016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of endurance training and/or fish oil supplemented diet on cytoplasmic fatty acid binding protein in rat skeletal muscles and heart.
    Clavel S; Farout L; Briand M; Briand Y; Jouanel P
    Eur J Appl Physiol; 2002 Jul; 87(3):193-201. PubMed ID: 12111278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effects of fenofibrate on the expression of peroxisome proliferator-activated-gamma coactivator-1α in skeletal muscle of rats infused with intralipid].
    Bai XP; Li HL; Yang WY; Xiao JZ; Wang B
    Zhonghua Yi Xue Za Zhi; 2010 Nov; 90(40):2856-9. PubMed ID: 21162799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The contribution of skeletal muscle tumor necrosis factor-alpha to insulin resistance and hypertension in fructose-fed rats.
    Togashi N; Ura N; Higashiura K; Murakami H; Shimamoto K
    J Hypertens; 2000 Nov; 18(11):1605-10. PubMed ID: 11081773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fenofibrate reverses changes induced by high-fat diet on metabolism in mice muscle and visceral adipocytes.
    Frias FT; Rocha KCE; de Mendonça M; Murata GM; Araujo HN; de Sousa LGO; de Sousa É; Hirabara SM; Leite NC; Carneiro EM; Curi R; Silveira LR; Rodrigues AC
    J Cell Physiol; 2018 Apr; 233(4):3515-3528. PubMed ID: 28926107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amelioration of high fructose-induced metabolic derangements by activation of PPARalpha.
    Nagai Y; Nishio Y; Nakamura T; Maegawa H; Kikkawa R; Kashiwagi A
    Am J Physiol Endocrinol Metab; 2002 May; 282(5):E1180-90. PubMed ID: 11934685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement of insulin sensitivity after peroxisome proliferator-activated receptor-alpha agonist treatment is accompanied by paradoxical increase of circulating resistin levels.
    Haluzik MM; Lacinova Z; Dolinkova M; Haluzikova D; Housa D; Horinek A; Vernerova Z; Kumstyrova T; Haluzik M
    Endocrinology; 2006 Sep; 147(9):4517-24. PubMed ID: 16740970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Muscle oxidative capacity is a better predictor of insulin sensitivity than lipid status.
    Bruce CR; Anderson MJ; Carey AL; Newman DG; Bonen A; Kriketos AD; Cooney GJ; Hawley JA
    J Clin Endocrinol Metab; 2003 Nov; 88(11):5444-51. PubMed ID: 14602787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic exercise provides renal-protective effects with upregulation of fatty acid oxidation in the kidney of high fructose-fed rats.
    Hu G; Xu L; Ma Y; Kohzuki M; Ito O
    Am J Physiol Renal Physiol; 2020 Mar; 318(3):F826-F834. PubMed ID: 32036700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum adipocyte fatty acid binding protein levels in patients with type 2 diabetes mellitus and obesity: the influence of fenofibrate treatment.
    Haluzík MM; Anderlová K; Doležalová R; Adamíková A; Haluzíková D; Housová J; Svacina S; Haluzík M
    Physiol Res; 2009; 58(1):93-99. PubMed ID: 18198986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of the Chinese medicine Jiang-Tang-Ke-Li on insulin resistance in fructose-fed rats.
    Wang L; Higashiura K; Togashi N; Saitoh S; Ura N; Shimamoto K
    Hypertens Res; 2001 May; 24(3):303-9. PubMed ID: 11409655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity.
    Furuhashi M; Ura N; Takizawa H; Yoshida D; Moniwa N; Murakami H; Higashiura K; Shimamoto K
    J Hypertens; 2004 Oct; 22(10):1977-82. PubMed ID: 15361770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A null mutation in H-FABP only partially inhibits skeletal muscle fatty acid metabolism.
    Binas B; Han XX; Erol E; Luiken JJ; Glatz JF; Dyck DJ; Motazavi R; Adihetty PJ; Hood DA; Bonen A
    Am J Physiol Endocrinol Metab; 2003 Sep; 285(3):E481-9. PubMed ID: 12900378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alteration of muscle fiber composition linking to insulin resistance and hypertension in fructose-fed rats.
    Higashiura K; Ura N; Takada T; Agata J; Yoshida H; Miyazaki Y; Shimamoto K
    Am J Hypertens; 1999 Jun; 12(6):596-602. PubMed ID: 10371369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different metabolic adaptation of heart and skeletal muscles to moderate-intensity treadmill training in the rat.
    Zonderland ML; Bär PR; Reijneveld JC; Spruijt BM; Keizer HA; Glatz JF
    Eur J Appl Physiol Occup Physiol; 1999 Apr; 79(5):391-6. PubMed ID: 10208246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight.
    Chaput E; Saladin R; Silvestre M; Edgar AD
    Biochem Biophys Res Commun; 2000 May; 271(2):445-50. PubMed ID: 10799317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effects of fenofibrate on gene expression of carnitine palmitoyltransferase 1 in liver and skeletal muscle and its influence on insulin sensitivity].
    Bai XP; Li HL; Yang WY; Xiao JZ; Wang B; Du RQ; Lou DJ
    Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(4):268-70. PubMed ID: 18361841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of an angiotensin-converting enzyme inhibitor and an angiotensin II receptor antagonist on insulin resistance in fructose-fed rats.
    Higashiura K; Ura N; Takada T; Li Y; Torii T; Togashi N; Takada M; Takizawa H; Shimamoto K
    Am J Hypertens; 2000 Mar; 13(3):290-7. PubMed ID: 10777034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome.
    Belfort R; Berria R; Cornell J; Cusi K
    J Clin Endocrinol Metab; 2010 Feb; 95(2):829-36. PubMed ID: 20061429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.